Cancer Care Ontario | Action Cancer Ontario

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

341 Results

Guidelines and Advice

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Status: Current
ID: GL END 9-10
Version: 2

Dec 1969

Blog post

A closer look at cancer drug shortages

While cancer drug shortages are not new, they are more frequent than ever. The reality today is that one or more cancer drugs may be in short supply...

Sep 2018

Application Instructions – Case-by-Case Review Program

Regimen

ANASRIBO

Cancer Type:

Breast

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

ODB - General Benefit

anastrozole

Exceptional Access Program

ribociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant according to clinical criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

anastrozole,

ribociclib

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Regimen

ANASPALB

Cancer Type:

Breast

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

ODB - General Benefit

anastrozole

Exceptional Access Program

palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

anastrozole,

palbociclib

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Cancer facts